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Summary
We used PET scans with the tracers []SF]fluorodeoxyglucose
(FDG) and [uC]raclopride (RACLO) to study glucose
metabolism and dopamine D2 receptor binding in the caudate
nucleus and putamen of 18 carriers of the Huntington's
disease gene mutation (10 asymptomatic subjects and eight
untreated symptomatic Huntington's disease patients in an
early disease stage). We also performed MRI scans and
measured the bicaudate ratio (BCR) in the same subjects.
Data were compared with those from nine mutation-negative
members of Huntington's disease families and separate
groups of age matched controls. The PET scans were
repeated 1.5-3 years later in six of the asymptomatic gene
carriers. Symptomatic Huntington 's disease patients showed
a marked reduction of FDG and RACLO uptake in the
caudate nucleus and putamen and a significant increase of
BCR. Asymptomatic mutation carriers revealed significant
hypometabolism in the caudate nucleus and putamen. The
RACLO binding was significantly decreased in the putamen.
Decrements of caudate nucleus tracer uptake, particularly
RACLO, correlated significantly with BCR increases in
both symptomatic and asymptomatic gene carriers. In
asymptomatic carriers, metabolic and receptor binding
decreases were also significantly associated with the CAG
repeat number but not with the individual's age. Discriminant
function analysis correctly classified clinical and genetic
status in 24 of 27 subjects on the basis of their striatal
PET values (83% sensitivity and 100% specificity). Three
asymptomatic mutation carriers were classified/grouped
together with mutation-negative subjects, indicating that
these individuals had normal striatal RACLO and FDG
uptake. Follow-up PET data from gene-positive subjects
showed a significant reduction in the mean striatal RACLO
binding of 6.3% per year. Striatal glucose metabolism
revealed an overall non significant 2.3% decrease per year.
These data indicate that asymptomatic Huntington's disease
mutation carriers may show normal neuronal function for a
long period of life. These findings also suggest that it may
be possible to predict when an asymptomatic gene carrier
will develop clinical symptoms from serial PET measurements
of striatal function.
Keywords: Huntington's disease; PET; MRI; glucose metabolism; dopamine D2 receptors
Abbreviations: BCR = bicaudate ratio; FDG = [18F]fluorodeoxyglucose; GMI = glucose metabolic index;
RACLO = ["CJraclopride; rCMRG = regional cerebral metabolic rate for glucose; ROI = region(s) of interest
Introduction
Huntington's disease is a dominantly inherited disorder
characterized by progressive dementia and chorea.
Symptomatic Huntington's disease patients show severe loss
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of striatal neurons (Vonsattel et al., 1985). In particular,
striatal spiny neurons expressing dopamine receptors are
primarily affected by the disease, whereas the presynaptic
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dopaminergic system is not involved (Reisine et al., 1978;
Spokes, 1980; Cross and Rosser, 1983; Reiner et al., 1988).
However, because post-mortem material from asymptomatic
gene carriers is extremely rare (Albin et al., 1992), very little
is known about changes taking place in the neurons before
the disease becomes clinically manifest. Knowledge of onset,
duration and progression of neuronal impairment before
clinical onset would also be relevant in view of possible
future treatment of yet asymptomatic Huntington's disease
mutation carriers with neuroprotective drugs or striatal
implantation methods.
PET studies in Huntington's disease have focused
mainly on the investigation of striatal glucose metabolism.
Symptomatic Huntington's disease patients revealed
significant hypometabolism in the basal ganglia (Kuwert
et al., 1990), whereas a reduction (Hayden et al., 1987;
Mazziotta et al., 1987) as well as normal glucose metabolism
(Young et al., 1987) have been shown in the caudate nucleus
in at risk subjects. In addition, PET studies of Huntington's
disease patients and asymptomatic at risk subjects have also
shown severe involvement of the postsynaptic dopaminergic
system but no change of dopaminergic nerve terminals
(Leenders et al., 1986; Hagglund et al., 1987; Brandt et al.,
1990; Ichise et al., 1993; Turjanski et al., 1995; Weeks
et al., 1996).
MRI has demonstrated tissue loss in the putamen and
caudate nucleus, not only of Huntington's disease patients
(Harris et al., 1992), but also of asymptomatic carriers
indicating that striatal atrophy may occur before the clinical
onset of chorea (Aylward et al., 1994). On the other hand,
there is evidence suggesting that striatal metabolism can be
significantly decreased in the absence of atrophy (Mazziotta
et al., 1987) and that metabolic and structural changes
may develop independently in the caudate nucleus (Grafton
et al, 1992).
Since the Huntington's disease mutation has been
discovered only recently (an expanded CAG triplet repeat in
the IT15 gene on chromosome 4p16.3; Huntington's Disease
Collaborative Research Group, 1993), most of the above
mentioned studies reported only likelihood, without definitive
assessment, of gene carrier status.
The purpose of this study was to assess the receptor
and metabolic status of striatal projection neurons in
genetically proven carriers of the Huntington's disease
mutation. We used PET and the tracers RACLO (dopamine
D2 antagonist) and FDG to investigate dopamine D2 receptor
binding and glucose metabolism in eight symptomatic and
10 asymptomatic Huntington's disease mutation carriers. To
assess the relationship between functional changes
expressed by PET and anatomical changes in the striatal
region, we also measured the BCR on MRI scans. In
addition, we performed discriminant function analysis to
assess whether the genetic and clinical status of the subjects
could be predicted from putamen and caudate nucleus
functional values.
Methods
Patients
Eight symptomatic Huntington's disease patients in an early
stage of the disease were studied (mean age 44±6 years;
Table 1 Subjects in this study
Subjects Age
(years)
Early stage Huntington's disease
1
2
3
4
5
6
7
8
Mean age
34
40
40
52
43
43
46
48
(±SD) = 44 (±6)
Sex
(male/female)
patients
m
m
f
m
m
m
f
m
Asymptomatic Huntington's disease mutation carriers
9
10
11
12
13
14
15
16
17
18
Mean age
21
27
28
29
30
41
35
34
27
26
(±SD) = 30 (±6)
f
m
f
f
m
f
m
m
m
f
Disease
duration (years)
3
2
2
3
1.5
1
1
4
-
_
_
_
—
—
_
_
—
_
CAG repeats
Expanded
48
46
44
42
42
42
44
44
47
43
42
45
46
43
46
40
45
42
Normal
19
20
17
17
17
19
18
17
24
22
22
23
19
13
18
10
18
16
Inheritance
(maternal/paternal)
P
m
m
P
m
m
m
m
P
P
P
P
m
P
P
m
m
P
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±SD here and throughout); their symptom duration was
between 5 months and 3 years (see Table 1); three patients
were at stage I and one at stage II according to the Shoulson
and Fahn scale (Shoulson and Fahn et ai, 1979). In addition,
10 asymptomatic carriers of the Huntington's disease mutation
(mean age 30±6 years) were studied (Table 1). Subjects 5
and 6 were monozygotic twins and both had chorea onset at
the age of 42 years. Among the 10 asymptomatic Huntington's
disease carriers, Subjects 10, 11 and 14 were siblings and
Subjects 9 and 13 were second cousins. The remaining
subjects belonged to unrelated pedigrees. None of the
individuals presented in this study had previously been
exposed to neuroleptics or other drugs which may influence
the dopaminergic system. Nine healthy mutation-negative
members of Huntington's disease families (mean age 27±4
years; range 22-34 years) were also studied with both PET
tracers as control subjects. Gene-negative subjects showed
no difference in their PET values when compared with
unrelated controls.
Each subject underwent a general neurological examination
before PET scanning. None of the asymptomatic mutation
carriers showed any sign of chorea, clinical abnormalities in
eye movements or other 'soft signs', as defined according to
a previously published scale (Young et al., 1986; Grafton
et al.. 1990). One asymptomatic Huntington's disease carrier
(no. 14) showed occasional subtle fidgeting of her limbs at
rest during one of the two PET measurements, but no other
abnormalities. This observation did not allow the diagnosis
of Huntington's disease in this person. Clinical investigations
were repeated in those asymptomatic gene carriers who had
a second series of PET scans. On that occasion none of the
subjects showed any sign of chorea. However, we detected
'soft signs' consisting of altered finger tapping control in
one (no. 14) and increased latency in saccade initiation and
mild slowing in saccade velocity in two of the six subjects
(nos 13 and 14).
Separate groups of healthy controls were used for
comparison. Data from the control subjects in this study
have been published previously (Antonini et al., \993b,
1995). For RACLO. data from 14 controls in the age range
of 21 —49 years (mean 3O±8 years) and for FDG, data from
20 other healthy subjects in the age range of 22^4 years
(mean 34±6 years) were used. The study was approved by
the ethical committee of the Zurich University Hospital.
Informed consent was obtained from each individual.
Genetic analysis
Predictive testing was performed in subjects at risk for
Huntington's disease according to recommended guidelines
(World Federation of Neurology 1989: see also Skraastad
et al.. 1991).
Standard procedures were used to isolate DNA from
blood (Miller et al., 1988). Amplification of the expanded
and normal (CAG)n-triplet sequences was carried out by
polymerase chain reaction (PCR) using previously published
primers (Riess et al., 1993). Individuals with CAG repeat
numbers higher than 37 were classified as Huntington's
disease gene carriers. The normal range was assumed to
be between 11 and 34 repeats (Huntington's Disease
Collaborative Research Group, 1993).
PET scanning procedure
The scanner used was a CTI/Siemens type 933/04—16,
with four rings, which records seven planes simultaneously
(transaxial resolution after reconstruction is 6.5 mm full
width at half maximum).
The subjects were positioned in the scanner using a
personalized head mould prepared by pouring urethane
foam into a polystyrene holder. The head was aligned
parallel to the orbitomeatal line using a laser beam. The
gantry field of view was chosen to cover the region
containing the complete striatum and the upper half of the
cerebellum. The same head mould and, where possible,
the same gantry coordinates were used to guarantee
precise repositioning. In six asymptomatic gene carriers
a stereotactic head fixation and repositioning system
(Fixster Instruments®, Stockholm, Sweden) was also used.
This head fixation system was used in five of the six
asymptomatic gene carriers who had follow-up scans. This
stereotactic frame ensures head repositioning with an error
of <1 mm.
After an initial 10 min transmission scan performed
using an external 68Ge ring source, RACLO (Ehrin et al.,
1987) or FDG were infused i.v. in 10 ml of physiological
saline for 3 min. The injected dose for both tracers ranged
from 112.2 to 226.4 MBq. The RACLO specific activity
at the time of injection was on average 1765 MBq |imol~'.
The FDG (16 time frames for a total of 48 min) and
RACLO (20 time frames for a total of 58 min) scans
were performed on separate occasions with an interval of
I day to 2 weeks.
The time course of plasma I8F activity was determined
by sampling radial arterial blood. From the FDG scan
and blood activity curves, parametric images of regional
cerebral metabolic rate for glucose (rCMRG expressed in
(imol min"1) were calculated on a pixel-by-pixel basis.
The lumped constant used was 0.52.
PET data analysis
[nC]Rac lop ride
Regions of interest (ROI) were placed on a video display
unit in a standard template arrangement on the putamen
(elliptical region of 250 mm2) and caudate nucleus (circular
region of 62.5 mm2). An integral image was produced by
adding the frames corresponding to the last 30 min of data
acquisition. The ROI were defined on this image, on the
plane where the maximal uptake was found and visually
adjusted to maximize the average ROI value. They were then
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superimposed on the dynamic data set to study time dependent
data. Cerebellar ROI (one circular region of 780 mm2 over
the cerebellar lobe of each hemisphere) were defined on one
of the lower planes in which the outline of the cerebellar
hemispheres was most clearly visible. For each time frame,
averaged radioactivity of each ROI was determined and
decay corrected to the start of tracer injection.
Specific RACLO binding in right and left putamen and
caudate nucleus was calculated for each subject 35-58 min
after tracer administration, using the ratio index of Farde
et al. (1986):
RACLO index = (target ROI activity - cerebellar activity)/
cerebellar activity.
The RACLO index values from the right and left brain
hemisphere were then averaged.
Longitudinal RACLO changes were calculated in % change
per year of the caudate and putamen index using the following
equation (Grafton et al., 1992):
% change per year = 100X[l - (2nd index/lst index)]/
(scan interval in years).
[l8F]Fluorodeoxy glucose
The ROI were placed on the plane where the anatomical
structure of putamen and caudate nucleus was most clearly
visible and visually adjusted to maximize the average ROI
value. The same standard template used for RACLO was
applied to define striatal ROI. On the same plane a global
ROI was defined (one ellipse adjusted in size to cover the
whole brain). To reduce intersubject variability, rCMRG ROI
values were then normalized to the corresponding global
values to calculate a glucose metabolic index (GMI). Values
of the right and left brain hemisphere were averaged.
Longitudinal FDG changes were calculated using the same
equation as for RACLO.
MRI data analysis
Subjects were studied with an MR Gyroscan (Philips) scanner
operating at 1.5 T. Seven of the eight Huntington's disease
patients and nine of the 10 asymptomatic mutation-positive
individuals also had MRI scanning. Each subject had their
MRI investigation within 1 week after PET. It was not
possible to obtain MRI data from mutation-negative subjects.
Twenty-five T2-weighted transverse contiguous slices (each
4 mm thick) were obtained using a spin-echo sequence from
each subject as previously reported (Antonini et al., 1993a).
The slice orientation was parallel to the orbitomeatal line.
The axial plane which cut through the mid-axial section of
the caudate nucleus was chosen. The BCR was calculated
by dividing the minimal distance between the caudate
indentations of the frontal horns by the distance between the
outer tables of the skull along the same line, then multiplying
by 100 (Barr et al., 1978). Patient PET and MRI data were
compared with those from a separate control group. Data
regarding these healthy subjects have been published before
(Antonini et al.,
Statistics
Data were analysed using the Systat (SYSTAT Inc., Evanston,
111., USA) statistic package. Mean values for each group were
compared using analysis of variance (ANOVA). Correlation
analysis was performed using single and multiple regression.
Discriminant functional analysis was used to categorize
subjects on the basis of their RACLO and FDG values in
the putamen and caudate nucleus and their BCRs. Specificity
[(true negative)/(true negative + false positive)] and
sensitivity [(true positive)/(true positive + false negative)]
were then calculated, based on discriminant analysis
categorization obtained from each of the above-mentioned
variables.
Results
Group comparisons
Figure 1 shows typical images of striatal FDG uptake and
RACLO binding in one Huntington's disease patient (Subject
4) and two asymptomatic gene carriers (Subjects 9 and 10).
Table 2 shows mean values for RACLO, FDG and BCR
in the caudate nucleus and putamen in symptomatic and
asymptomatic Huntington's disease carriers and controls.
Symptomatic Huntington 's disease patients
Caudate nucleus. Symptomatic Huntington's disease
patients revealed severely reduced RACLO [F(l,20) =
230.9, P < 0.0001] and GMI [F(l,26) = 204.0, P <
0.0001] values and significantly increased BCR [F(l,15) =
63.8, P < 0.0001] compared with unrelated controls.
Compared with asymptomatic mutation carriers,
symptomatic Huntington's disease patients showed
significantly lower FDG [F(l,16) = 131.0, P < 0.0001]
and RACLO [F(l,16) = 28.9, P < 0.0001] values and
increased BCR [F(l,14) = 22.5, P < 0.0003]. No
correlation was present between the RACLO index and
GMI in the symptomatic Huntington's disease (Fig. 2A).
The BCR increases correlated significantly with decrements
of RACLO binding (r = 0.88, P < 0.006) (Fig. 3) but
not with FDG changes. No correlation was found between
RACLO, GMI or BCR values and the individual's age or
CAG number.
Putamen. Symptomatic Huntington's disease patients
showed a reduced RACLO [F(l,20) = 156.2, P < 0.0001]
and FDG [F(l,26) = 86.8, P < 0.0001] index compared with
controls. Compared with asymptomatic mutation carriers,
symptomatic Huntington's disease patients revealed a
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Huntingtons Disease
[18F]FDG
Clinically manifest Asymptomatic gene carriers
[11C]Raclopride
Fig. 1 Representative PET images of FDG {top row) and RACLO {bottom row) at the mid-striatal level from: on the left, a symptomatic
Huntington's disease patient (no. 4) showing marked reduction of striatal glucose metabolism and RACLO binding; in the middle, an
asymptomatic mutation-positive subject (no. 9) showing reduced striatal glucose metabolism and RACLO binding and on the right, an
asymptomatic mutation-positive subject (no. 10) still showing values in the control range. The RACLO images were obtained by adding
the frames corresponding to the last 30 min of data acquisition. Each FDG and RACLO images is scaled relative to common maximum
and background levels.
significant reduction of FDG [F(l,16) = 33.4, P < 0.0001]
and RACLO [F(1,I6) = 44.1, P < 0.0001] values. The
RACLO and FDG decreases were not significantly correlated
(Fig. 2B). The RACLO, GMI or BCR values did not correlate
with the individual's age or CAG number.
Asymptomatic mutation carriers
Caudate nucleus. Asymptomatic mutation carriers showed
significantly reduced FDG values [F(l,28) = 8.0, P < 0.009]
compared with unrelated controls, but no significant change
in RACLO and BCR values. The BCR increases correlated
significantly with decrements of RACLO (r = 0.76, P <
0.02) (Fig. 3) and of FDG (r = 0.75, P < 0.02) (Fig. 2A).
No correlation was present between RACLO and FDG values.
The GMI values did not correlate with the individual's
age or CAG number. The RACLO index was significantly
correlated with the CAG repeat length (r = -0.652; P <
0.04) but not with the subject's age.
Putamen. Subjects with the asymptomatic mutation showed
reduced RACLO [F(\,26) = 7.1, P < 0.02] and FDG
[F(l,26) = 7.5, P < 0.02) compared with controls. The
RACLO and FDG decrements were significantly correlated
(r = 0.69, P < 0.03) (Fig. 2B). The CAG repeat number
significantly correlated with the RACLO index (r = -0.740;
P < 0.02) and GMI values (r = -0.761; P < 0.009) (Fig.
4A and B). No correlation was found with the individual's age.
RACLO and FDG follow-up scans
Figure 5 shows representative images of FDG (left) and
RACLO (right) at the mid-striatal level from one
asymptomatic mutation-positive subject (no. 12) at the time
of the first PET measurements and 3 years later.
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Table 2 Results from PET and MR1 scans
Subjects
Early stage Huntington'.
1
2
3
4
5
6
7
8
Mean
SD
Asymptomatic mutation
9
10
11
12
13
14
15
16
17
18
Mean
SD
Caudate nucleus
PET-RACLO
index
> disease patients (n =
0.78
0.92
0.96
1.09
1.15
1.07
1.05
0.90
0.99***
0.12
carriers (n = 10)
1.58
2.97
2.42
2.29
1.92
1.57
1.70
3.31
3.07
2.85
2.37
0.66
Mutation-negative Huntington's disease family
Mean
SD
Unrelated controls
Mean
SD
2.81
0.44
2.85
0.25
PET-FDG
(GMI)
8)
0.68
0.87
0.73
0.79
0.71
0.60
0.74
0.72
0.73***
0.08
.09
.13
.24
.02
.06
.06
.09
.15
.15
.17
.12**
0.07
members (n = 9)
.19
0.04
1.18
0.06
MRI
(BCR)
13.80
12.50
NA
10.60
10.20
11.30
12.70
14.10
12.17***
1.52
9.20
5.80
5.90
9.80
8.70
8.70
10.90
6.00
7.50
NA
8.06
1.86
NA
NA
7.59
0.71
Putamen
PET-RACLO
index
0.78
0.57
0.88
1.15
0.76
0.65
0.83
1.00
0.83***
0.18
1.63
3.08
2.45
2.30
1.84
1.72
1.56
3.24
2.66
2.68
2.32*
0.61
2.85
0.40
2.75
0.35
PET-FDG
(GMI)
0.71
0.86
1.10
0.96
0.78
084
0.89
0.90
0.88***
0 12
1.04
1.25
1.28
1.09
1.10
1.19
1.05
1.19
1.22
1.31
1.17*
0.10
1.22
0.10
1.26
0.07
NA = not available. ••*/> < 0.0001, **P < 0.01 and *P < 0.02 (ANOVA compared with controls).
After 1.5-3 years, RACLO values were significantly
reduced in the six asymptomatic mutation carriers in the
caudate nucleus (P < 0.03) and putamen (P < 0.03). Changes
of FDG values did not reach statistical significance (caudate,
P = 0.21; putamen, P = 0.058). Interestingly, the only
asymptomatic gene carrier who showed no measurable PET
change was one of the three individuals classified as normal
by discriminant function analysis. Since the putamen and
caudate nucleus showed similar degrees of change in all
subjects, values from the two regions were averaged to
calculate an overall %reduction for the whole striatum.
Striatal RACLO values in each subject are plotted as a
function of time in Fig. 6. On the first PET scan, mean
striatal values for RACLO and FDG were 2.15±0.52 and
1.13±0.09. In the follow-up PET scans values were 1.90±0.6
for RACLO and 1.08±0.12 for FDG. The overall decline
was 6.3% per year for RACLO and 2.3% per year for FDG.
We did not detect any difference in the rate of progression
in relation to the individual's CAG repeat number or the
gender of the affected parent.
Discriminant function analysis
Discriminant functional analysis was first performed on the
three groups (Huntington's disease patients, asymptomatic
mutation carriers and mutation-negative relatives) considering
RACLO and FDG uptake in the caudate nucleus and putamen
each as separate variables. The best categorization was
obtained with caudate nucleus FDG uptake which showed
83% sensitivity and 78% specificity. Putamen-FDG revealed
a 78% sensitivity and 66% specificity. The RACLO sensitivity
was 78% for the caudate nucleus (specificity 66%) and
78% for the putamen (specificity 78%). However, when
considering the four dependent variables together, discrimin-
ant analysis classification was consistent with clinical and
genetic status in 24 of 27 individuals with a 84% sensitivity
and a specificity of 100% (Wilks' lambda = 0.065; [F(8,42) =
15.3, P < 0.0001]. The remaining three subjects were
asymptomatic gene carriers who were assigned to the same
category as mutation-negative controls, indicating that these
individuals had normal RACLO and FDG uptake in the
caudate nucleus and putamen (Fig. 7). We also performed
! 1
(A)
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Fig. 2 Scatter diagram of the caudate nucleus (A) and putamen
(B) FDG-GMI and RACLO indices for symptomatic (solid
circles), asymptomatic mutation carriers (open triangles) and
mutation-negative Huntington's disease family members (squares).
The three asymptomatic carriers classified as normal by
discriminant function analysis are indicated by large open
triangles. Mean values of RACLO and GMI for unrelated healthy
controls are indicated by the solid square. Error bars indicate
2XSD of the control mean.
discriminant analysis on MRI BCR data. Since MRI data for
the mutation-negative group were not available, we used data
from symptomatic and asymptomatic carriers, and from a
separate control group. Specificity for the BCR was 66% and
its sensitivity 76%.
Multiple regression analysis
Stepwise multiple regression analysis was performed on data
from all symptomatic and asymptomatic mutation carriers to
determine the relative contribution of sex, age, parental
transmission and CAG repeat number to the prediction of
RACLO, FDG and BCR values. Only the combination
of the CAG repeat number and the individual's age
significantly predicted all variables.
Results for the caudate nucleus were for FDG, F = 16.2
(adjusted R2 = 0.640, P < 0.005); for RACLO, F = 28.2
(adjusted R2 = 0.762, P < 0.001); for BCR, F = 44.2 (adjusted
R2 = 0.852, P<0 .00 l ) .
cr
O 10CD A
A A
Caudate RACLO index
Fig. 3 Scatter diagram of the caudate nucleus RACLO index and
MRI-BCR for symptomatic (solid circles) and asymptomatic
mutation carriers (open triangles).
Results for the putamen were: for FDG, F = 8.2 (adjusted
R2 = 0.459, P < 0.005); for RACLO, F = 22.9 (adjusted
R2 = 0.721, P < 0.001).
Discussion
Our study demonstrates that asymptomatic Huntington's
disease mutation carriers may show normal striatal
metabolism and receptor function early in life. On the other
hand, symptomatic Huntington's disease patients revealed a
severe hypometabolism and loss of striatal dopamine D2
receptor binding sites.
Previous PET studies have already shown reduced glucose
metabolism in the caudate nucleus of Huntington's disease
patients (Hayden et al., 1987; Mazziotta et al., 1987; Kuwert
etai, 1990). However, the finding of glucose hypometabolism
does not indicate which neuronal subpopulation is primarily
affected by the genetic mutation. Neuropathological studies
have revealed that striatal neurons expressing dopamine
receptors are affected early in Huntington's disease (Reisine
et al., 1978; Spokes, 1980; Cross and Rosser, 1983; Reiner
et al., 1988). Since dopamine D2 receptors are mainly located
on postsynaptic membranes, the reduction of striatal RACLO
binding can be considered a direct marker of neuronal loss
in Huntington's disease-mutation carriers. Because loss of
binding sites was more severe in symptomatic than
asymptomatic mutation carriers, we suggest that choreatic
symptoms become clinically manifest only when receptor
density, and thus neuronal density, is below a certain
threshold.
In our study, metabolic and receptor decrements were
associated with significant increases of the MRI BCR. The
relationship between anatomical and functional changes in
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Fig. 4 Scatter diagram of the putamen RACLO index (A) and
FDG-GMI values (B) with individual CAG repeat numbers in
asymptomatic gene carriers. The RACLO and FDG values did not
correlate with individual subject age, neither did the CAG
number.
Huntington's disease has never been clearly addressed before.
Barr et al. (1978) showed a significant enlargement of
the bicaudate diameter in patients with clinically manifest
Huntington's disease. Ayl ward et al. (1994) found a significant
reduction of basal ganglia volume in 10 asymptomatic carriers
indicating that anatomical changes may be present before
chorea is clinically evident. However, Grafton et al. (1992)
found no correlation between the rate of change of caudate
size and glucose metabolism in nine asymptomatic at risk
subjects and suggested that metabolic loss and atrophy may
develop independently. In addition, Mazziotta et al. (1987)
showed significant hypometabolism but no evidence of
caudate atrophy at CT scanning in subjects at risk for
Huntington's disease. Indeed, in our study asymptomatic
Huntington's disease gene carriers showed no significant
BCR changes in spite of significant caudate nucleus
hypometabolism. This finding suggests that, at least in the
pre-symptomatic phase of the disease, striatal atrophy is
not a major contributor to the reduced striatal function in
Huntington's disease.
We also found that the CAG repeat number and the
individual's age were the only two significant predictors of
MRI and PET changes when considering all symptomatic
and asymptomatic Huntington's disease gene carriers. In
particular we found that in the asymptomatic carrier group,
even in the narrow range of repeats in our patient sample
(40-47), the CAG repeat length (but not age) still correlated
significantly with both PET functional values. The finding
of a significant association between metabolic and receptor
binding decreases, and size of the Huntington's disease
mutation is in keeping with previous genetic studies indicating
that the CAG repeat number is the main determinant of
Huntington's disease onset and progression (Ashizawa et al.,
1994; Garcia-Ruiz et al., 1995). However, the mechanisms
by which the expansion of the CAG repeats causes the
Huntington's disease phenotype are not completely
understood. The enlarged CAG repeat is translated into a
protein, named huntingtin, which has been detected in
neuronal cell bodies and nerve endings, has unknown function
and shows no specific regional distribution (Landwehrmeyer
etai, 1995; Trottier et al., 1995). The prominence of neuronal
loss in the striatum indicates that striatal projection neurons
may have some still unknown characteristics that makes
them particularly vulnerable to the Huntington's disease
mutation product.
The glucose metabolism data and receptor binding in the
putamen and caudate nucleus were consistent with genetic
and clinical status in 24 of 27 of subjects with a sensitivity
of 83% and 100% specificity. Hayden et al. (1987) reported
a significant hypometabolism in only three of eight individuals
at high risk (37%). On the other hand, Grafton et al. (1990)
reported a relative sensitivity of 75% for caudate nucleus
metabolism data, which is similar to our results, but only
33% for the BCR. In contrast to other authors (Young et al.,
1986; Grafton et al., 1990) we did not detect soft signs in
our asymptomatic mutation carriers at the time of the first
PET measurements. This may be due to the lower mean age
of our asymptomatic carriers compared with other studies.
Also differences in the size of the CAG expansion between
the investigated patient populations may explain discrepancies
between the above mentioned studies regarding sensitivity of
PET or MRI measurements, or frequency of mild neurological
abnormalities in asymptomatic carriers.
Follow-up scans showed a significant 6.3% decline per
year of striatal RACLO binding and an insignificant 2.3%
reduction of glucose metabolism in our asymptomatic gene
carriers. Only one subject (no. 10) showed no metabolic or
receptor decrement after 2 years: this subject was one of the
three individuals classified as normal by discriminant function
analysis. Based on published data on test-retest variability
of FDG and RACLO values, the metabolic and receptor
binding changes in our subjects exceeded those one would
expect if they were determined only by chance (Grafton
et al., 1992; Volkow et al., 1993). In addition, decrements
- Metabolism and receptor-binding in~Huntington 's disease 2093
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Fig. 5 Representative images of FDG (left) and RACLO values (right) at the mid-striatal level from an asymptomatic mutation-positive
subject (no. 12) at the time of the first PET measurements (top row) and 3 years later (bottom row). The second scan series shows
reduced striatal glucose metabolism (-15%) and RACLO binding (-18%) compared with the first one.
were greater than those we would expect due to normal
ageing. To our knowledge, there is no evidence of a decline
in striatal glucose metabolism with ageing. Conversely, we
have previously reported that striatal RACLO uptake declines
0.6% per year in normal subjects. However, this would
account for only 10% of the mean year decrease we have
reported in our six asymptomatic carriers. The 2.3% loss per
year of striatal glucose metabolism in asymptomatic carriers
is similar to the 3.1% per year reported earlier by Grafton
et al. (1992). These authors estimated that, given a metabolic
loss of 2-3% per year, at least 15 gene carriers should be
scanned with a time interval of 42 months between the two
PET studies to detect a statistically significant reduction in
caudate glucose metabolism. In our study RACLO decrements
were more prominent and reached statistical significance
after an average time interval of 2 years in only six subjects.
This suggests that dopamine D2 receptor binding may be a
more sensitive measure of outcome in terms of striatal
neuronal loss than glucose metabolism. Our data also suggest
that, assuming a constant decline in RACLO binding, an
asymptomatic gene carrier starting from the control mean
will reach a RACLO index value 2XSD below the normal
mean after 4.5 years. After a further 9 years, he will reach
a value 2XSD above the mean of symptomatic Huntington's
disease patients, when their chorea becomes clinically
manifest.
In conclusion, our results demonstrate that molecularly
proven carriers of the Huntington's disease mutation can
show normal neuronal function for many years, as expressed
by regional glucose consumption and dopamine D2 receptor
binding. Our findings also suggest that the measurement of
striatal metabolism and dopamine D2 receptor binding can
be used as a specific marker of disease progression in
Huntington's disease.
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Fig. 6 Scatter diagram of the caudate nucleus RACLO index from
the first and second scans in six asymptomatic mutation carriers.
The solid square shows the control mean; the solid circle shows
the mean of the Huntington's disease patients. Error bars indicate
2XSD of the mean. Numbers identify the asymptomatic mutation
carriers as listed in Table 1.
HD patients Asymptomatic
mutation +
Control
(mutation -)
Fig. 7 Scatter diagram of the score obtained from the
discriminant function analysis of symptomatic and asymptomatic
mutation carriers and mutation-negative Huntington's disease
(HD) family members, based on RACLO and FDG values of
caudate nucleus and putamen. The three asymptomatic carriers
classified as normal by the analysis are indicated with large filled
triangles.
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